A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response

[1]  M. Reed,et al.  Differential Monocyte Activation Underlies Strain-Specific Mycobacterium tuberculosis Pathogenesis , 2004, Infection and Immunity.

[2]  C. Buchrieser,et al.  Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. , 2004, Microbiology.

[3]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[4]  M. Daffé,et al.  Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex. Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene. , 2002, The Journal of biological chemistry.

[5]  S. Salzberg,et al.  Whole-Genome Comparison of Mycobacterium tuberculosis Clinical and Laboratory Strains , 2002, Journal of bacteriology.

[6]  Koichi Suzuki,et al.  Mycobacterium leprae Infection in Monocyte-Derived Dendritic Cells and Its Influence on Antigen-Presenting Function , 2002, Infection and Immunity.

[7]  D. van Soolingen,et al.  Worldwide Occurrence of Beijing/W Strains of Mycobacterium tuberculosis: A Systematic Review , 2002, Emerging infectious diseases.

[8]  Barun Mathema,et al.  Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. , 2002, Trends in microbiology.

[9]  T. Parish,et al.  Mycobacterium tuberculosis protocols , 2001 .

[10]  H. Sprecher,et al.  The Mycobacterium tuberculosis pks2 Gene Encodes the Synthase for the Hepta- and Octamethyl-branched Fatty Acids Required for Sulfolipid Synthesis* , 2001, The Journal of Biological Chemistry.

[11]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. E. Barry,et al.  Analysis of the Lipids of Mycobacterium tuberculosis. , 2001, Methods in molecular medicine.

[13]  R. Timpl,et al.  Role of the Cell Wall Phenolic Glycolipid-1 in the Peripheral Nerve Predilection of Mycobacterium leprae , 2000, Cell.

[14]  William R. Jacobs,et al.  Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice , 1999, Nature.

[15]  R. North,et al.  Growth Rate of Mycobacteria in Mice as an Unreliable Indicator of Mycobacterial Virulence , 1999, Infection and Immunity.

[16]  P. Haslett,et al.  Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. , 1999, Journal of immunology.

[17]  M. Daffé,et al.  Interaction of mycobacterial glycolipids with host cells. , 1998, Frontiers in bioscience : a journal and virtual library.

[18]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[19]  I. Onorato,et al.  An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. , 1998, The New England journal of medicine.

[20]  W. Jacobs,et al.  Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Whittam,et al.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Azad,et al.  Biochemistry and molecular genetics of cell‐wall lipid biosynthesis in mycobacteria , 1997, Molecular microbiology.

[23]  D. Young,et al.  Mycobacteria as Immunogens: Development of Expression Vectors for Use in Multiple Mycobacterial Species , 1997 .

[24]  D. Young,et al.  Transformation of mycobacterial species using hygromycin resistance as selectable marker. , 1994, Microbiology.

[25]  L. Faccioli,et al.  Suppression of human monocyte cytokine release by phenolic glycolipid-I of Mycobacterium leprae. , 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[26]  W. Jacobs,et al.  New use of BCG for recombinant vaccines , 1991, Nature.

[27]  R. Mullins,et al.  Inhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids , 1989, Infection and immunity.

[28]  B. Andersen,et al.  Suppression of monocyte oxidative response by phenolic glycolipid I of Mycobacterium leprae. , 1989, Journal of immunology.

[29]  J. Convit,et al.  Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid , 1984, Nature.

[30]  P. Brennan,et al.  A novel phenolic glycolipid from Mycobacterium leprae possibly involved in immunogenicity and pathogenicity , 1981, Journal of bacteriology.